APA (7th ed.) Citation

SG, v. R., JJ, d. H., H, G., MJL, N., MHS, H., MAJ, G., . . . IME, D. (2025). Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(17), 3678. https://doi.org/10.1158/1078-0432.CCR-25-0311

Chicago Style (17th ed.) Citation

SG, van Ravensteijn, et al. "Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 31, no. 17 (2025): 3678. https://doi.org/10.1158/1078-0432.CCR-25-0311.

MLA (9th ed.) Citation

SG, van Ravensteijn, et al. "Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 31, no. 17, 2025, p. 3678, https://doi.org/10.1158/1078-0432.CCR-25-0311.